The Chemours Company $CC Stock Holdings Lowered by Private Management Group Inc.

Private Management Group Inc. lessened its stake in The Chemours Company (NYSE:CC) by 15.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 642,364 shares of the specialty chemicals company’s stock after selling 117,978 shares during the quarter. Private Management Group Inc.’s holdings in Chemours were worth $8,717,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Chemours in the 2nd quarter valued at about $477,769,000. Wolf Hill Capital Management LP bought a new position in Chemours in the 2nd quarter worth about $59,698,056. Bank of New York Mellon Corp bought a new position in Chemours in the 2nd quarter worth about $33,353,000. Bank of America Corp DE increased its position in shares of Chemours by 79.1% during the first quarter. Bank of America Corp DE now owns 1,317,003 shares of the specialty chemicals company’s stock worth $29,014,000 after acquiring an additional 581,621 shares during the period. Finally, Legal & General Group Plc purchased a new position in shares of Chemours during the second quarter worth approximately $28,400,000. Institutional investors own 76.26% of the company’s stock.

Analyst Upgrades and Downgrades

CC has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Chemours in a research note on Tuesday, November 3rd. BMO Capital Markets dropped their price objective on Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a research note on Thursday, August 13th. Royal Bank Of Canada cut Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 price objective on the stock. in a research note on Tuesday, October 13th. Truist Financial reduced their price objective on Chemours from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, November 4th. Finally, Zacks Research lowered Chemours from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 4th. Three analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Chemours presently has an average rating of “Hold” and an average price target of $17.36.

Key Headlines Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Stronger titanium dioxide pricing and growth in Advanced Performance Materials (APM) partly offset weak Thermal & Specialized Solutions (TSS) volumes in the third quarter. Zacks Q3 earnings report
• Negative Sentiment: Multiple law firms publicized a securities class action filed against Chemours and certain officers. The suit covers investors who acquired shares from February 20 through August 4, 2026, and alleges that the company misrepresented or failed to disclose weakening Opteon aftermarket demand while reaffirming its 2026 outlook. These are allegations, not established findings; the lead-plaintiff deadline is December 7. The litigation adds legal and reputational risk. Pomerantz class action announcement
• Negative Sentiment: Chemours’ third-quarter EPS of $0.21 fell short of the $0.26 analyst consensus, with weak TSS volumes weighing on results, despite revenue slightly exceeding expectations. Zacks Q3 earnings report
• Negative Sentiment: JPMorgan lowered its price target from $15 to $14 and maintained a Neutral rating, signaling more limited expected upside. JPMorgan rating information

Chemours Stock Up 1.4%

NYSE:CC opened at $13.46 on Wednesday. The Chemours Company has a 1-year low of $10.44 and a 1-year high of $28.67. The company has a 50-day moving average of $13.87 and a 200 day moving average of $18.19. The firm has a market cap of $2.03 billion, a PE ratio of -13.20 and a beta of 1.47. The company has a debt-to-equity ratio of 24.25, a current ratio of 1.81 and a quick ratio of 0.98.

Chemours (NYSE:CC) last issued its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.26 by ($0.05). The business had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.53 billion. Chemours had a positive return on equity of 76.52% and a negative net margin of 2.64%. The firm’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.40 earnings per share. As a group, research analysts anticipate that The Chemours Company will post 0.82 EPS for the current fiscal year.

Chemours Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be given a $0.0875 dividend. This represents a $0.35 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, November 16th. Chemours’s dividend payout ratio is presently -34.31%.

Chemours Profile

The Chemours Company is a global chemicals manufacturer spun off from DuPont in 2015 and headquartered in Wilmington, Delaware. It develops and produces materials used in industries ranging from construction and transportation to electronics and energy. Chemours’ Titanium Technologies business makes titanium dioxide (TiO₂) pigment, sold under the Ti-Pure brand, which is used to add whiteness, brightness and opacity to products such as paints, coatings, plastics and paper. Its Thermal & Specialized Solutions business supplies refrigerants, foam-blowing agents and other specialty fluids, including products marketed under the Opteon and Freon brands.